These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Proceedings: Influence of a single intravenous dose of phenytoin on to EEG. Hrazdira C; Zouhar A; Hrazdirová V; Skálová M Electroencephalogr Clin Neurophysiol; 1975 Oct; 39(4):437-8. PubMed ID: 51772 [No Abstract] [Full Text] [Related]
23. [Decrease of folic acid and cognitive alterations in patients with epilepsy treated with phenytoin or carbamazepine, pilot study]. Hernández R; Fernández Mde L; Miranda G; Suástegui R Rev Invest Clin; 2005; 57(4):522-31. PubMed ID: 16315636 [TBL] [Abstract][Full Text] [Related]
24. Clinical trial on sustained-release phenytoin. Preliminary results of the open, non-controlled study. The Phenytoin Trial Group on Canine Epilepsy. Overduin LM Tijdschr Diergeneeskd; 1992 Apr; 117 Suppl 1():27S-28S. PubMed ID: 1585316 [No Abstract] [Full Text] [Related]
25. High-dose phenytoin in the treatment of refractory epilepsy. Cobos JE Epilepsia; 1987; 28(2):111-4. PubMed ID: 3816707 [TBL] [Abstract][Full Text] [Related]
26. More on phenytoin injection precautions. Clin Pharm; 1986 Sep; 5(9):717. PubMed ID: 3757445 [No Abstract] [Full Text] [Related]
28. [Electrophysiologic changes after taking sodium phenytoin]. Guo SS Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1986 Dec; 19(6):360-1. PubMed ID: 3582030 [No Abstract] [Full Text] [Related]
29. Life-threatening cardiotoxicity due to chronic oral phenytoin overdose. Su CM; Kung CT; Wang YC; Lu CH Neurol India; 2009; 57(2):200-2. PubMed ID: 19439856 [TBL] [Abstract][Full Text] [Related]
30. [Metabolic and immunological disorders induced by long-term treatment with phenytoin]. Saskowski M; Pupek-Musialik D; Rybicka K Neurol Neurochir Pol; 1978; 12(3):321-5. PubMed ID: 355910 [No Abstract] [Full Text] [Related]
31. How to give phenytoin safely. Report from a long-term care facility in North Carolina. Pulliam C; Pait L; Winslow J N C Med J; 1996; 57(5):292-5. PubMed ID: 8854693 [No Abstract] [Full Text] [Related]
32. Recognizing and managing purple glove syndrome. Snelson C; Dieckman B Crit Care Nurse; 2000 Jun; 20(3):54-61. PubMed ID: 11876214 [No Abstract] [Full Text] [Related]
33. Soft-tissue damage associated with intravenous phenytoin. Kilarski DJ; Buchanan C; Von Behren L N Engl J Med; 1984 Nov; 311(18):1186-7. PubMed ID: 6482941 [No Abstract] [Full Text] [Related]
34. [EEG findings and phenytoin concentration in the serum of children with epilepsy]. Wässer S; Jalinski W; Meyer FP; Walther H Padiatr Grenzgeb; 1984; 23(2):87-92. PubMed ID: 6728491 [No Abstract] [Full Text] [Related]
35. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Boucher BA; Feler CA; Dean JC; Michie DD; Tipton BK; Smith KR; Kramer RE; Young B; Parks BR; Kugler AR Pharmacotherapy; 1996; 16(4):638-45. PubMed ID: 8840370 [TBL] [Abstract][Full Text] [Related]
36. [Myoclonic encephalopathy caused by isoniazid-hydantoin combination]. Destee A; Verrier A; Gelez P; Warot P Lille Med; 1979 Jan; 24(1):41-5. PubMed ID: 431301 [No Abstract] [Full Text] [Related]
37. Inadvertent chronic diphenylhydantoin intoxication in a teenage girl. Herberg KP J S C Med Assoc; 1972 Sep; 68(9):350-3. PubMed ID: 4506856 [No Abstract] [Full Text] [Related]
38. [Survival period of patients with gliomata or glioblastomata under anti-convulsive therapy (author's transl)]. Sayk J; Kmietzyk HJ Nervenarzt; 1981 Oct; 52(10):611-5. PubMed ID: 6272140 [No Abstract] [Full Text] [Related]
39. Inadequate serum levels after intramuscular administration of diphenylhydantoin. Wilensky AJ; Lowden JA Neurology; 1973 Mar; 23(3):318-24. PubMed ID: 4735182 [No Abstract] [Full Text] [Related]